Substance Spotlight: Inhalants Are the Overdose Crisis Nobody Is Watching, and It's Getting Younger

Every 10th day of the year, this spotlight rotates to a substance class we don’t cover often enough. Today it’s inhalants — and the numbers are worth sitting with, because inhalants don’t get a task force, a naloxone equivalent, or much of a place in the national conversation at all. A drug class you can buy at a gas station, that kills on the first use as easily as the hundredth, gets almost no public health infrastructure built around it — and the people most likely to use it are children.

The numbers nobody talks about

The 2024 National Survey on Drug Use and Health, released by SAMHSA in mid-2025, found that 1.1% of Americans 12 and older — about 3.2 million people — used an inhalant in the past year. That number alone might not sound alarming next to opioid or stimulant figures. What should stop you is the age breakdown: 3.7% of 12-to-17-year-olds (roughly 967,000 teenagers) used an inhalant in the past year — nearly double the rate among young adults 18-25 (2.0%) and more than five times the rate among adults over 26 (0.7%). Inhalant misuse is, disproportionately and by a wide margin, a teenager’s drug. It’s also one of the only substance classes where availability is essentially unregulated: whipped-cream chargers, computer duster, keyboard cleaner, glue, aerosol deodorant. Nothing about buying any of these requires an ID, a dealer, or even leaving a convenience store.

What actually kills

Here’s the mechanism, in plain terms, because “inhalants” as a category hides how dangerous a single use can be. Many inhalants — particularly halogenated hydrocarbons, the class found in aerosols, refrigerants, and solvents — can trigger a fatal irregular heartbeat known as sudden sniffing death syndrome. It doesn’t require chronic use, tolerance, or a large dose. A 2025 review in the journal Addiction makes the point starkly: a single inhalant session, for a person who has never used one before, can be fatal, and resuscitation is rarely successful once the arrhythmia starts because the mechanism — sensitizing the heart to a person’s own adrenaline — works too fast for typical overdose-response training to catch. There is no naloxone equivalent. The only real protection is not doing it in the first place, and if you’re with someone who does, knowing that any sign of distress needs immediate emergency care, not a wait-and-see approach.

The current wave: nitrous oxide, rebranded and flavored

The specific product driving 2026’s legislative attention is nitrous oxide sold under flavored, colorfully packaged brand names — most visibly Galaxy Gas — marketed and displayed in ways that read less like industrial whipped-cream chargers and more like a vape product. The FDA issued a safety warning in March 2025 about injuries tied to these flavored canisters. By 2026, states started responding directly: Washington Governor Bob Ferguson signed HB 2532 in March, banning unauthorized recreational sale of nitrous oxide and explicitly naming flavored, branded products like Galaxy Gas as the target; South Carolina’s legislature advanced a similar bill in February after families of young people harmed by the products testified directly to lawmakers. No federal consumer-product ban has followed yet — this is happening state by state, unevenly, the way most inhalant policy has for thirty years. Families of people injured by these products have begun filing civil claims against manufacturers and retailers; those cases are still working through courts, and specific injury and death counts circulating in press coverage of the litigation haven’t been independently verified against court filings or FDA’s MedWatch adverse-event database, so treat exact figures with caution until they are.

If you’ve ever stood in a smoke shop or a party-supply aisle and clocked the wall of flavored canisters without registering them as a drug product, that’s by design — nothing about the packaging is built to trigger the caution a needle or a pill bottle would. That’s precisely why “just a whipped-cream charger” is doing a lot of work to make a fatal-on-first-use product feel like nothing.

That’s precisely why “just a whipped-cream charger” is doing a lot of work to make a fatal-on-first-use product feel like nothing.

The historical through-line: we named this problem in 1992 and then mostly stopped

This isn’t the first time the country has noticed inhalants and organized around it. The National Inhalant Prevention Coalition established National Inhalants and Poisons Awareness Week in 1992 — observed every year in the third week of March — making it one of the longest-running substance-specific youth prevention campaigns in the country, older than most opioid-era harm-reduction infrastructure entirely. It was built on the same basic finding this piece opened with: inhalants kill young people, fast, with products already sitting in most households. Thirty-four years later, the awareness week still runs quietly every March, largely unchanged in scale, while the products themselves have been rebranded, flavored, and given social-media-native names and packaging that make them look nothing like the aerosol cans the 1992 campaign was built to warn about. The policy response — a patchwork of state bills advancing one legislature at a time — looks a great deal like the response in 1992: real, well-intentioned, and perpetually smaller than the problem it’s addressing.

Where this leaves a provider or a parent

If you work with adolescents in any clinical or case-management capacity, inhalant screening is worth asking about directly and without judgment — teenagers rarely bring it up unprompted, both because it doesn’t fit the mental image of “drug use” they’ve been taught to disclose, and because the products themselves are legal, cheap, and sitting in a kitchen cabinet. A single conversation about what’s actually in the house — dusters, chargers, solvents — costs nothing and takes five minutes at a routine visit or a team meeting, and the NSDUH data above says the population most likely to benefit from that conversation is exactly the population showing up in a pediatric or school-based caseload.

The state-by-state legislative wave this year is real progress, and it’s also, per the thirty-four-year history above, likely to plateau the way it has before: awareness campaigns and piecemeal bans, chasing a product category that keeps rebranding faster than policy can catch up. What hasn’t changed since 1992 is the actual protective step, which doesn’t require a new law: knowing the signs, knowing that a single use can be fatal, and treating any inhalant exposure as a medical emergency the moment something looks wrong.